CEP-18770
Updated: Nov 14, 2009
| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | 1/2 |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that CEP-18770 demonstrated superior activity to Velcade (bortezomib), and it caused fewer side effects during treatment.
Clinical Trials:
For a list of clinical trials studying CEP-18770 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Related Articles:
- None Found
